Tafluprost, a new potent prostanoid receptor agonist: A dose-response study on pharmacodynamics and tolerability in healthy volunteers

Sutton A., Gouws P., Ropo A.

2008
International Journal of Clinical Pharmacology and Therapeutics

View publication

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

Guildford Clinical Pharmacology Ltd., Technology Center, Guildford, Surrey, United Kingdom; Conquest Hospital, Ridge, St. Leonards-on-Sea, East Sussex, United Kingdom; Santen Oy Clinical Research, Tampere, Finland; Cedars Vanzell Road, Midhurst, West Sussex GU29 9BA, United Kingdom

Related Publications

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.

Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study.

Bacharach, Jason; McLaurin, Eugene B.; Silverstein, Steven; Amrane, Mourad; Garrigue, Jean-Sebastien; Ismail, Dahlia; Flynn, William J.; Catiolanze Phase 2 study group

Assessment of Brain-Derived Neurotrophic Factor on Retinal Structure and Visual Function in Rodent Models of Optic Nerve Crush

Taniguchi T.; Sharif N.A.; Ota T.; Farjo R.A.; Rausch R.

View all Glaucoma publications